137 related articles for article (PubMed ID: 32903213)
21. MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinoma.
Yang H; Gu J; Wang KK; Zhang W; Xing J; Chen Z; Ajani JA; Wu X
Clin Cancer Res; 2009 Sep; 15(18):5744-52. PubMed ID: 19737949
[TBL] [Abstract][Full Text] [Related]
22. Exosomal onco-miRs from serum of patients with adenocarcinoma of the esophagus: comparison of miRNA profiles of exosomes and matching tumor.
Warnecke-Eberz U; Chon SH; Hölscher AH; Drebber U; Bollschweiler E
Tumour Biol; 2015 Jun; 36(6):4643-53. PubMed ID: 25631748
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA alterations in Barrett's esophagus, esophageal adenocarcinoma, and esophageal adenocarcinoma cell lines following cranberry extract treatment: Insights for chemoprevention.
Kresty LA; Clarke J; Ezell K; Exum A; Howell AB; Guettouche T
J Carcinog; 2011; 10():34. PubMed ID: 22279419
[TBL] [Abstract][Full Text] [Related]
24. LINE-1 expression and retrotransposition in Barrett's esophagus and esophageal carcinoma.
Doucet-O'Hare TT; Rodić N; Sharma R; Darbari I; Abril G; Choi JA; Young Ahn J; Cheng Y; Anders RA; Burns KH; Meltzer SJ; Kazazian HH
Proc Natl Acad Sci U S A; 2015 Sep; 112(35):E4894-900. PubMed ID: 26283398
[TBL] [Abstract][Full Text] [Related]
25. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
[TBL] [Abstract][Full Text] [Related]
26. Chronic Obstructive Pulmonary Disease and the Risk of Esophagitis, Barrett's Esophagus, and Esophageal Adenocarcinoma: A Primary Care Case-Control Study.
Menon S; Nightingale P; Trudgill N
J Clin Gastroenterol; 2019; 53(10):e451-e455. PubMed ID: 31008868
[TBL] [Abstract][Full Text] [Related]
27. miR-200 family expression is downregulated upon neoplastic progression of Barrett's esophagus.
Smith CM; Watson DI; Leong MP; Mayne GC; Michael MZ; Wijnhoven BP; Hussey DJ
World J Gastroenterol; 2011 Feb; 17(8):1036-44. PubMed ID: 21448356
[TBL] [Abstract][Full Text] [Related]
28. Circulating miRNAs in patients with Barrett's esophagus, high-grade dysplasia and esophageal adenocarcinoma.
Pavlov K; Kluiver J; Meijer C; Boersma-van Ek W; Kruyt FAE; Karrenbeld A; Kleibeuker JH; Peters FTM; van den Berg A
J Gastrointest Oncol; 2018 Dec; 9(6):1150-1156. PubMed ID: 30603135
[TBL] [Abstract][Full Text] [Related]
29. Laryngopharyngeal reflux symptoms better predict the presence of esophageal adenocarcinoma than typical gastroesophageal reflux symptoms.
Reavis KM; Morris CD; Gopal DV; Hunter JG; Jobe BA
Ann Surg; 2004 Jun; 239(6):849-56; discussion 856-8. PubMed ID: 15166964
[TBL] [Abstract][Full Text] [Related]
30. Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma.
Derks S; Nason KS; Liao X; Stachler MD; Liu KX; Liu JB; Sicinska E; Goldberg MS; Freeman GJ; Rodig SJ; Davison JM; Bass AJ
Cancer Immunol Res; 2015 Oct; 3(10):1123-1129. PubMed ID: 26081225
[TBL] [Abstract][Full Text] [Related]
31. Novel Aberrations Uncovered in Barrett's Esophagus and Esophageal Adenocarcinoma Using Whole Transcriptome Sequencing.
Maag JLV; Fisher OM; Levert-Mignon A; Kaczorowski DC; Thomas ML; Hussey DJ; Watson DI; Wettstein A; Bobryshev YV; Edwards M; Dinger ME; Lord RV
Mol Cancer Res; 2017 Nov; 15(11):1558-1569. PubMed ID: 28751461
[TBL] [Abstract][Full Text] [Related]
32. Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia.
Anaparthy R; Gaddam S; Kanakadandi V; Alsop BR; Gupta N; Higbee AD; Wani SB; Singh M; Rastogi A; Bansal A; Cash BD; Young PE; Lieberman DA; Falk GW; Vargo JJ; Thota P; Sampliner RE; Sharma P
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1430-6. PubMed ID: 23707463
[TBL] [Abstract][Full Text] [Related]
33. Persistence of nondysplastic Barrett's esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort.
Gaddam S; Singh M; Balasubramanian G; Thota P; Gupta N; Wani S; Higbee AD; Mathur SC; Horwhat JD; Rastogi A; Young PE; Cash BD; Bansal A; Vargo JJ; Falk GW; Lieberman DA; Sampliner RE; Sharma P
Gastroenterology; 2013 Sep; 145(3):548-53.e1. PubMed ID: 23714382
[TBL] [Abstract][Full Text] [Related]
34. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression.
Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717
[TBL] [Abstract][Full Text] [Related]
35. Esophageal Adenocarcinoma and Its Rare Association with Barrett's Esophagus in Henan, China.
Liu S; Dai JY; Yao L; Li X; Reid B; Self S; Ma J; Chang Y; Feng S; Tapsoba Jde D; Sun X; Sun X
PLoS One; 2014; 9(10):e110348. PubMed ID: 25333822
[TBL] [Abstract][Full Text] [Related]
36. Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia.
Parasa S; Vennalaganti S; Gaddam S; Vennalaganti P; Young P; Gupta N; Thota P; Cash B; Mathur S; Sampliner R; Moawad F; Lieberman D; Bansal A; Kennedy KF; Vargo J; Falk G; Spaander M; Bruno M; Sharma P
Gastroenterology; 2018 Apr; 154(5):1282-1289.e2. PubMed ID: 29273452
[TBL] [Abstract][Full Text] [Related]
37. Response to TNF-α Is Increasing Along with the Progression in Barrett's Esophagus.
Chemnitzer O; Götzel K; Maurer L; Dietrich A; Eichfeld U; Lyros O; Jansen-Winkeln B; Hoffmeister A; Gockel I; Thieme R
Dig Dis Sci; 2017 Dec; 62(12):3391-3401. PubMed ID: 29086334
[TBL] [Abstract][Full Text] [Related]
38. Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma.
Kao SC; Cheng YY; Williams M; Kirschner MB; Madore J; Lum T; Sarun KH; Linton A; McCaughan B; Klebe S; van Zandwijk N; Scolyer RA; Boyer MJ; Cooper WA; Reid G
J Thorac Oncol; 2017 Sep; 12(9):1421-1433. PubMed ID: 28629895
[TBL] [Abstract][Full Text] [Related]
39. Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence.
Mokrowiecka A; Veits L; Falkeis C; Musial J; Kordek R; Lochowski M; Kozak J; Wierzchniewska-Lawska A; Vieth M; Malecka-Panas E
Pathol Res Pract; 2017 Mar; 213(3):205-209. PubMed ID: 28216140
[TBL] [Abstract][Full Text] [Related]
40. Immune determinants of Barrett's progression to esophageal adenocarcinoma.
Lagisetty KH; McEwen DP; Nancarrow DJ; Schiebel JG; Ferrer-Torres D; Ray D; Frankel TL; Lin J; Chang AC; Kresty LA; Beer DG
JCI Insight; 2021 Jan; 6(1):. PubMed ID: 33290281
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
